BeiGene USA was granted orphan designation from the FDA for a treatment of mantle cell lymphoma, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BGNE:
- BeiGene to present new data on hematology portfolio and pipeline
- BeiGene treatment of multiple myeloma granted orphan designation
- BeiGene, Ensem Therapeutics partner on CDK2 inhibitor
- BeiGene receives European Commission approval for BRUKINSA
- BeiGene price target raised to $200 from $180.18 at BofA
Questions or Comments about the article? Write to editor@tipranks.com